BR112023018210A2 - Composições e métodos para remover nanopartículas biossintéticas de fluidos corporais - Google Patents
Composições e métodos para remover nanopartículas biossintéticas de fluidos corporaisInfo
- Publication number
- BR112023018210A2 BR112023018210A2 BR112023018210A BR112023018210A BR112023018210A2 BR 112023018210 A2 BR112023018210 A2 BR 112023018210A2 BR 112023018210 A BR112023018210 A BR 112023018210A BR 112023018210 A BR112023018210 A BR 112023018210A BR 112023018210 A2 BR112023018210 A2 BR 112023018210A2
- Authority
- BR
- Brazil
- Prior art keywords
- biosynthetic
- nanoparticles
- compositions
- methods
- baited
- Prior art date
Links
- 230000001851 biosynthetic effect Effects 0.000 title abstract 8
- 239000002105 nanoparticle Substances 0.000 title abstract 7
- 210000001124 body fluid Anatomy 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000010839 body fluid Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
- A61F2/064—Blood vessels with special features to facilitate anastomotic coupling
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3687—Chemical treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Anesthesiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Abstract
composições e métodos para remover nanopartículas biossintéticas de fluidos corporais. a presente invenção refere-se a métodos e composições de isca e captura para remover nanopartículas biossintéticas de fluidos corporais. as nanopartículas biossintéticas são iscadas com uma metade de um complexo de isca e captura e liofilizadas. a nanopartícula biossintética iscada é reconstituída e administrada a um indivíduo para fins diagnósticos ou terapêuticos. para remover a nanopartícula biossintética do corpo, o fluido corporal contendo o nanoartigo biossintético iscado é colocado em contato com a porção de captura do complexo de isca e captura. o fluido corporal do qual foram removidas as nanopartículas biossintéticas pode ser retornado para o indivíduo.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163159547P | 2021-03-11 | 2021-03-11 | |
PCT/US2022/019872 WO2022192619A1 (en) | 2021-03-11 | 2022-03-11 | Compositions and methods for removing bio-synthetic nano-particles from bodily fluids |
US17/692,289 US20220287984A1 (en) | 2021-03-11 | 2022-03-11 | Compositions and methods for removing bio-synthetic nano-particles from bodily fluids |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112023018210A2 true BR112023018210A2 (pt) | 2023-10-03 |
Family
ID=83195350
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112023018210A BR112023018210A2 (pt) | 2021-03-11 | 2022-03-11 | Composições e métodos para remover nanopartículas biossintéticas de fluidos corporais |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220287984A1 (pt) |
EP (1) | EP4304654A1 (pt) |
JP (1) | JP2024509957A (pt) |
KR (1) | KR20230155462A (pt) |
CN (1) | CN117500526A (pt) |
AU (1) | AU2022232631A1 (pt) |
BR (1) | BR112023018210A2 (pt) |
CA (1) | CA3210619A1 (pt) |
IL (2) | IL305814A (pt) |
MX (1) | MX2023010613A (pt) |
WO (1) | WO2022192619A1 (pt) |
ZA (1) | ZA202308676B (pt) |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4169079A (en) * | 1977-10-24 | 1979-09-25 | Iwao Tabushi | Polystyrene based polymers containing cyclodextrin derivatives, metal complexes of the same, and process for the production of the same |
EP1587408A4 (en) * | 2002-12-20 | 2007-09-05 | Momenta Pharmaceuticals Inc | GLYCAN MARKER FOR DIAGNOSIS AND MONITORING OF DISEASES |
US8246565B2 (en) * | 2009-02-25 | 2012-08-21 | The Invention Science Fund I, Llc | Device for passively removing a target component from blood or lymph of a vertebrate subject |
US11291644B2 (en) * | 2012-09-04 | 2022-04-05 | Eleison Pharmaceuticals, Llc | Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin |
CA2910380C (en) * | 2013-05-03 | 2020-09-29 | Washington University | Blood substitute composition and method of use |
WO2016050210A1 (zh) * | 2014-10-01 | 2016-04-07 | 厦门赛诺邦格生物科技有限公司 | 一种多官能化聚乙二醇衍生物及其制备方法 |
CN104877127B (zh) * | 2015-06-23 | 2017-11-10 | 厦门赛诺邦格生物科技股份有限公司 | 一种八臂聚乙二醇衍生物、制备方法及其修饰的生物相关物质 |
CN111134116B (zh) * | 2020-01-02 | 2021-10-26 | 中化化工科学技术研究总院有限公司 | 一种甲维盐水分散粒剂及其制备方法 |
-
2022
- 2022-03-11 MX MX2023010613A patent/MX2023010613A/es unknown
- 2022-03-11 EP EP22768047.7A patent/EP4304654A1/en active Pending
- 2022-03-11 JP JP2023555536A patent/JP2024509957A/ja active Pending
- 2022-03-11 CA CA3210619A patent/CA3210619A1/en active Pending
- 2022-03-11 US US17/692,289 patent/US20220287984A1/en active Pending
- 2022-03-11 IL IL305814A patent/IL305814A/en unknown
- 2022-03-11 IL IL305815A patent/IL305815A/en unknown
- 2022-03-11 WO PCT/US2022/019872 patent/WO2022192619A1/en active Application Filing
- 2022-03-11 BR BR112023018210A patent/BR112023018210A2/pt unknown
- 2022-03-11 KR KR1020237031318A patent/KR20230155462A/ko unknown
- 2022-03-11 AU AU2022232631A patent/AU2022232631A1/en active Pending
- 2022-03-11 CN CN202280020656.2A patent/CN117500526A/zh active Pending
-
2023
- 2023-09-11 ZA ZA2023/08676A patent/ZA202308676B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA3210619A1 (en) | 2022-09-15 |
JP2024509957A (ja) | 2024-03-05 |
WO2022192619A1 (en) | 2022-09-15 |
ZA202308676B (en) | 2024-04-24 |
MX2023010613A (es) | 2023-09-20 |
US20220287984A1 (en) | 2022-09-15 |
IL305815A (en) | 2023-11-01 |
CN117500526A (zh) | 2024-02-02 |
AU2022232631A1 (en) | 2023-09-21 |
EP4304654A1 (en) | 2024-01-17 |
KR20230155462A (ko) | 2023-11-10 |
IL305814A (en) | 2023-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP4233861A3 (en) | Compositions for treatment of essential tremor | |
RU2018110647A (ru) | Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний | |
BR112013017628A2 (pt) | composição de proteína de soro com uma adstringência reduzida | |
BRPI0512893A (pt) | métodos de determinação da eficácia da terapia no tratamento da amiloidose e de identificação de paciente como prodrÈmico para doença associada com a deposição amilóide e respectivos compostos | |
EA200601799A1 (ru) | Гидразидсодержащие соединения - ингибиторы cftr и их применение | |
Smith | Intradermal sodium thiosulfate for exophytic calcinosis cutis of connective tissue disease | |
AR109103A1 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
MA41150B1 (fr) | Polymères de liaison aux protons pour administration orale | |
EA202090242A1 (ru) | Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов | |
MX2017017136A (es) | Composicion para el tratamiento de la nafld. | |
BR112015030623A2 (pt) | agentes citotóxicos para o tratamento de câncer | |
BR112023018210A2 (pt) | Composições e métodos para remover nanopartículas biossintéticas de fluidos corporais | |
BR112023021131A2 (pt) | Tratamento de tremor essencial | |
RU2015112121A (ru) | Ми-рнк и их применение в способах и композициях для лечения и/или профилактики глазных состояний | |
Makedonova et al. | Studying clinical and pathomorphological changes in gingival tissues when applying platelet-rich autoplasma regenerative method | |
BR112017023493A2 (pt) | composições que compreendem cinamaldeído e zinco e métodos de uso de tais composições | |
RU2012151952A (ru) | Способ создания плевродеза | |
JP6100510B2 (ja) | 抗感冒剤 | |
EA200900214A1 (ru) | Фармацевтическая композиция рифабутина для лечения туберкулеза, способ ее получения и способ лечения | |
JP6641263B2 (ja) | 神経障害性疼痛の処置方法 | |
CL2021003312A1 (es) | Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma. | |
Elsholkamy | A novel treatment for temporomandibular joint internal derangement: a randomized controlled clinical study | |
RU2375066C2 (ru) | Способ профилактики ранних послеоперационных тромбоэмболических осложнений | |
Yuksel et al. | Multiple widespread epidermal cysts of the skin: an unusual presentation | |
BR112018002433A2 (pt) | composição farmacêutica para tratamento da enxaqueca |